BERLIN, Conn., Aug. 5, 2021 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Apixaban Tablets (generic for Eliquis®). This product was developed by Towa Pharmaceutical Europe, S.L. in its manufacturing facility located in Martorelles, Spain. According to industry sales data, Eliquis generated annual sales of $14 billion during the twelve months ending May 2021. Breckenridge has been granted a license under confidential terms permitting Breckenridge to launch generic Apixaban Tablets under its Abbreviated New Drug Application at a later date.
About Breckenridge: Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients. With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and quality of life of the patients we and our customers serve. www.bpirx.com
For further information, please contact: Breckenridge Pharmaceutical, Inc. Robert Gasparino, Associate Vice President – Business Development Tel: 860-828-8140 E-mail: [email protected]
*All brand names and trademarks are the property of their respective owners.